Revolutionizing Preclinical Research: iMouse’s AI-Powered Digital Biomarkers Transform Drug Discovery and Animal Welfare

Berlin, Germany – May 28, 2026 – In a significant leap forward for medical technology, Berlin-based startup iMouse is reshaping the landscape of preclinical drug development. By transforming conventional laboratory animal housing into sophisticated, AI-powered digital observation units, iMouse promises a future where drug testing is more precise, cost-effective, and, crucially, significantly more humane. This innovation addresses long-standing challenges in pharmaceutical research, aiming to save billions in wasted investment and accelerate the delivery of life-saving medicines.

Authored by Ute Häußler, this report delves into the technology and vision of iMouse, exploring its profound implications for science, industry, and ethical practice.

The Unseen Challenge in Drug Discovery

For decades, the foundation of preclinical drug testing has relied on methods that, while established, are inherently limited. The journey of a potential drug, from initial concept to market, is fraught with hurdles, none more critical than the early assessment of its efficacy and safety in animal models.

A Legacy of Manual Observation

Imagine a scene common in countless research facilities worldwide: a dedicated animal caretaker, clipboard in hand, peering into a standard polycarbonate "Makrolonbox" housing laboratory rodents. This snapshot observation, often subjective and periodic, forms the basis for data that can dictate multi-billion-dollar investment decisions in drug development. Dr. Janine Kah, a seasoned biologist and co-founder of iMouse, intimately understands this reality from her years in preclinical research, a reality that increasingly sparked her critical questioning.

"Are we, perhaps, missing crucial signals due to the very nature of our data collection?" Dr. Kah pondered. In traditional setups, behavioral changes indicative of potential side effects or efficacy are manually documented, captured sporadically, and evaluated through a human lens. What goes unnoticed within the confines of a lab box during these fleeting observations may only surface much later as a severe symptom in human clinical trials, leading to devastating setbacks.

The Cost of Missed Signals

The stakes in drug discovery are astronomically high. Today, an alarming 90 percent of all drug candidates entering clinical development ultimately fail. This staggering failure rate not only consumes immense research time – often a decade or more – but also devours astronomical sums of capital, ultimately inflating the cost of approved medications. The inability to make robust "Go/No-Go" decisions earlier in the preclinical phase is a major contributor to this inefficiency.

This glaring inefficiency, coupled with the ethical imperative to refine animal testing, fueled the inception of iMouse. Dr. Kah’s vision, shared by CEO and co-founder Mirko Lampe, posits a provocative yet increasingly undeniable truth: the pharmaceutical industry, despite investing billions in advanced technologies like AI, might be fundamentally undermined by the quality of data gathered by a human with a clipboard.

The Observer Effect as a Blind Spot

At the heart of this problem lies a fundamental biological challenge known as the "observer effect." Mice and rats, being nocturnal creatures, perceive humans as natural predators. Their instinctual response to a human presence is a protective reflex, altering their natural behavior. "The animals behave as if they are fine when a human is present. We simply don’t see many crucial effects," explains Mirko Lampe. "And these flawed observations then become the basis for ‘Go/No-Go’ decisions that dictate our progression to clinical trials."

Dr. Kah underscores the critical nature of this problem: "The crucial question is: ‘How can we conduct experiments better and more reproducibly?’" The answers, they discovered, lay in embracing continuous, unbiased digital observation.

iMouse: A Digital Revolution for the Lab

Over the past five years, iMouse has diligently developed a sophisticated technology platform designed to address these deeply rooted issues in preclinical research. Their solution integrates seamlessly into existing laboratory environments, providing a non-invasive, data-rich approach to animal observation.

Genesis of an Innovation

The journey began with Dr. Kah’s firsthand experience in preclinical research, where she witnessed the inherent limitations and potential biases of manual observation. Her scientific rigor prompted her to seek a more reliable and objective methodology. Teaming up with Mirko Lampe, whose entrepreneurial drive and technical acumen complemented her biological expertise, they founded iMouse. Their shared conviction was that cutting-edge technology, specifically AI and advanced imaging, could bridge the critical data gap in early drug development. Their mission: to make animal experimental insights more dependable, paving the way for better, faster, and more ethical drug discoveries.

Silent Sentinels: The Technology Behind iMouse

The core of the iMouse system is a modular camera platform, the "DigiFrame," designed to retrofit standard "Home Cages" – the conventional housing units for laboratory animals. This ingenious system transforms these ordinary enclosures into continuous, 24/7 observation units, critically, without requiring any human intervention or disturbing the animals from their natural environment.

Equipped with high-resolution cameras and advanced Artificial Intelligence, the iMouse system automatically captures and analyzes animal behavior and activity rhythms. A proprietary Multi-Frame-Transformer architecture, developed over years, can currently recognize nine distinct behavioral patterns in mice. These range from fundamental activities like sleep and rest phases, eating, and drinking, to more critical indicators such as abnormal activities or even seizure-like events. This continuous, objective data stream provides an unprecedented level of detail and accuracy previously unattainable through intermittent manual checks.

Pioneering Digital Biomarkers

What iMouse introduces to preclinical research is a concept long established in clinical medicine: the digital biomarker. "These simply do not exist in the preclinical environment, and certainly not in a standardized way," states Lampe. By continuously tracking and correlating multiple behavioral biomarkers – such as movement activity, feeding patterns, and sleep rhythms – researchers can draw early conclusions about the potential effects of a candidate drug.

This capability enables what iMouse terms "Early Efficacy" detection. It’s the earliest possible evidence of whether a compound works at all, long before a pharmaceutical company commits hundreds of millions of euros to subsequent, costly development phases. Identifying ineffective compounds early prevents monumental financial losses and allows resources to be reallocated to more promising candidates.

Transforming Lab Operations and Ethics

The benefits of the iMouse system extend beyond mere data collection, significantly impacting daily lab operations and advancing ethical standards in animal research.

Minimizing Disturbance, Maximizing Data

Ursula Müller, an animal caretaker at the Heinrich Pette Institute, eloquently describes the current challenges: "Today, the animal caretaker is forced to pick up the cage, and possibly open it – yet the mouse is in its resting phase during the day. In the worst case, the animal has to be individually examined under the workbench. This is a huge disturbance."

This profound disturbance, a major source of stress for the animals and a confounder for research data, is precisely what the iMouse cameras aim to eliminate. By providing continuous, non-invasive monitoring, the system allows animals to exhibit their natural behaviors without interruption, leading to more authentic and reliable data.

Seamless Integration and Secure Data

From a technical standpoint, iMouse emphasizes seamless integration into existing lab infrastructure. The DigiFrame hardware module is designed as a retrofit, attaching to Home Cages from all major manufacturers without requiring any structural modifications. Equipped with infrared light at 920 nanometers, the system enables undisturbed night observation, crucial for studying nocturnal rodents.

All data converges via the iMouse platform hub, offering remote access, an alarm function for critical events, and flexible AI analysis options – either local or cloud-based. Critically, the system is fully compliant with stringent data protection regulations such as the GDPR and the forthcoming AI Act, ensuring data integrity and privacy.

A Proactive Approach to Animal Welfare (The 3Rs)

The animal-friendly approach championed by iMouse resonates deeply with evolving regulatory frameworks. The "3R principles" – Replace, Reduce, Refine – are statutory standards globally, guiding ethical animal experimentation. Furthermore, "New Approach Methodologies" (NAMs), which prioritize animal-free or animal-reduced methods, are gaining significant political momentum at the EU level and beyond.

iMouse strategically positions itself not as a complete replacement for animal testing, but as a powerful tool for refinement and reduction. By generating deeper, more accurate data with fewer animals, and by minimizing stress through non-invasive observation, the system directly supports the spirit and letter of the 3R principles. This argumentation holds substantial weight both regulatorily and economically, fostering a more responsible and sustainable approach to preclinical research.

Tangible Impact and Future Horizons

The vision behind iMouse extends far beyond incremental improvements, promising a paradigm shift with profound economic and scientific implications.

Proving Efficacy: Early Adopters and Validation

The technological validation of the iMouse system is now complete, and the company is actively in its scaling phase. Already, over 40 systems are in operation at ten key customers across Europe, including prestigious institutions such as the German Center for Neurodegenerative Diseases (DZNE) in Bonn, Ludwig Maximilian University (LMU) Munich, the Max Planck Institute Dresden, the renowned Francis Crick Institute in the UK, and the biotherapeutics manufacturer CSL Behring. This rapid adoption by leading research organizations underscores the recognized value and robustness of the iMouse platform.

Billions on the Line: The Economic Imperative

The economic dimension of iMouse’s innovation is staggering. A drug candidate halted during Phase II or III clinical trials typically incurs several hundred million euros in development costs – investments that are entirely written off. More reliable preclinical data, enabling earlier "Go/No-Go" decisions, could systematically reduce these catastrophic losses.

This forms the core of iMouse’s promise to pharmaceutical companies: not just more data for better algorithms, but a significantly earlier, more reliable discontinuation point in drug discovery. An industry expert, requesting anonymity due to proprietary insights, commented, "The ability to cut losses earlier is not just about saving money; it’s about freeing up capital and talent to pursue more promising avenues. This kind of preclinical precision could fundamentally alter the ROI landscape for R&D."

The Electronic Health Record for Every Mouse

iMouse’s long-term vision extends beyond behavioral data. Collaborating with institutions like Fraunhofer, the company is already working on integrating additional data sources. Future iterations will incorporate implant-based sensors to provide continuous physiological data such as body temperature and heart rate. Furthermore, integration with Laboratory Information Management Systems (LIMS) will embed crucial metadata like animal strain, age, and sex.

The ultimate goal is to create a comprehensive "electronic health record" for each individual animal. This digital dossier will then lay the groundwork for developing a "digital twin" of the preclinical model – a robust, virtual bridge between animal experimentation and human clinical outcomes. Such a twin could revolutionize predictive modeling, allowing researchers to simulate drug effects with unprecedented accuracy.

Shaping the Regulatory Landscape

As political and societal pressure mounts for more ethical and efficient research practices, iMouse finds itself perfectly aligned with emerging regulatory trends. The increasing emphasis on NAMs by legislative bodies, particularly in the EU, creates a fertile ground for technologies that can demonstrably reduce the number of animals used while enhancing the quality of data. iMouse’s commitment to generating greater data depth with fewer animals, through gentle, non-invasive methods, positions it as a crucial enabler for laboratories seeking to meet these evolving standards.

Conclusion: A New Era for Preclinical Research

The nearly 20-strong team at iMouse is driven by a singular ambition: to assess every single drug candidate earlier, more precisely, and more reproducibly. By providing an accurate, unbiased preclinical data foundation, they are not just optimizing a process; they are orchestrating a paradigm shift.

iMouse represents a powerful convergence of cutting-edge artificial intelligence, ethical considerations, and economic imperatives. Its innovation offers a tangible pathway to accelerate the development of new treatments, reduce the financial burden of pharmaceutical R&D, and uphold the highest standards of animal welfare. In an era demanding both scientific rigor and ethical responsibility, iMouse stands as a beacon for a more intelligent, humane, and efficient future in preclinical research, ultimately benefiting human health worldwide.